AQR Capital Management LLC Purchases 9,254 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

AQR Capital Management LLC increased its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 76.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 21,296 shares of the company’s stock after buying an additional 9,254 shares during the period. AQR Capital Management LLC’s holdings in Nurix Therapeutics were worth $444,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of NRIX. Affinity Asset Advisors LLC grew its holdings in Nurix Therapeutics by 12.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 912,000 shares of the company’s stock worth $19,033,000 after acquiring an additional 101,747 shares during the last quarter. Alpha DNA Investment Management LLC acquired a new position in Nurix Therapeutics during the second quarter worth $427,000. Caxton Associates LP grew its position in Nurix Therapeutics by 100.9% during the second quarter. Caxton Associates LP now owns 30,767 shares of the company’s stock valued at $642,000 after buying an additional 15,453 shares during the period. Squarepoint Ops LLC bought a new position in Nurix Therapeutics during the second quarter valued at about $601,000. Finally, Fred Alger Management LLC bought a new position in Nurix Therapeutics during the second quarter worth about $794,000.

Nurix Therapeutics Stock Down 1.2 %

Shares of Nurix Therapeutics stock opened at $24.87 on Wednesday. The stock has a market cap of $1.22 billion, a PE ratio of -8.52 and a beta of 2.22. Nurix Therapeutics, Inc. has a 12 month low of $4.22 and a 12 month high of $26.31. The business has a fifty day simple moving average of $23.44 and a 200-day simple moving average of $19.42.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 264.84% and a negative return on equity of 67.78%. The company had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. Analysts expect that Nurix Therapeutics, Inc. will post -2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NRIX. Robert W. Baird started coverage on shares of Nurix Therapeutics in a research note on Friday, September 6th. They issued an “outperform” rating and a $26.00 target price on the stock. HC Wainwright boosted their target price on Nurix Therapeutics from $19.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, June 18th. Royal Bank of Canada lowered their price objective on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday. Truist Financial began coverage on shares of Nurix Therapeutics in a report on Wednesday, July 31st. They issued a “buy” rating and a $36.00 target price for the company. Finally, JPMorgan Chase & Co. increased their price objective on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Monday, July 15th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $28.71.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the sale, the chief financial officer now directly owns 54,479 shares in the company, valued at approximately $1,126,080.93. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Nurix Therapeutics news, insider Christine Ring sold 9,870 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $25.01, for a total value of $246,848.70. Following the completion of the sale, the insider now owns 24,592 shares of the company’s stock, valued at $615,045.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $51,468.30. Following the transaction, the chief financial officer now directly owns 54,479 shares in the company, valued at $1,126,080.93. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,105 shares of company stock valued at $1,507,181 over the last three months. 7.20% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.